Neurocritical Care

, Volume 15, Issue 3, pp 400–404

High-Dose Intra-Arterial Nicardipine Results in Hypotension Following Vasospasm Treatment in Subarachnoid Hemorrhage

  • Neil Rosenberg
  • Marc A. Lazzaro
  • Demetrius K. Lopes
  • Shyam Prabhakaran
Original Article



Intra-arterial (IA) nicardipine is often used to treat cerebral vasospasm associated with subarachnoid hemorrhage (SAH). While hypotension has been noted to be a dose-limiting side effect of intravenous infusions, this has seldom been reported for IA administration.


We reviewed a consecutive series of patients who received IA nicardipine for SAH-associated vasospasm. Nicardipine was titrated to angiographic response, with blood pressure and intracranial pressure monitoring. We analyzed data using Wilcoxon signed rank, Student’s t-test, Spearman’s correlation, and χ2 statistics as appropriate. A P value <0.05 was considered significant.


Thirty patients underwent 50 procedures in which nicardipine was the sole chemical vasodilator (median dose, 15 mg). Median mean arterial pressures (MAP) decreased from 118 to 100 mmHg (P < 0.001), with an intra-operative low of 80 mmHg. Both intra-operative and post-operative decreases in MAP were directly related to nicardipine dose (rs = 0.352, P = 0.022 and rs = 0.308, P = 0.047, respectively). Hypotension (MAP < 70 mmHg) occurred in 22%, and 44% required initiation of or increases in vasopressor therapy. After the first treatment, 11 of 16 patients treated with vasodilator therapy alone, and 5 of 14 patients who underwent additional balloon angioplasty (68.8 vs. 35.7%, P = 0.141), required further endovascular treatments due to recurrent vasospasm on subsequent days.


Intra-arterial nicardipine is associated with significant intra-operative blood pressure lowering, an increased requirement for intra-operative vasopressor therapy, and a tendency toward re-treatment when used as initial monotherapy for vasospasm.


Vasodilator Calcium-channel blockers Blood pressure Angioplasty Intracranial Pressure 


  1. 1.
    Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40:994–1025.PubMedCrossRefGoogle Scholar
  2. 2.
    Longstreth WT Jr, Nelson LM, Koepsell TD, van Belle G. Clinical course of spontaneous subarachnoid hemorrhage: a population-based study in King County, Washington. Neurology. 1993;43:712–8.PubMedGoogle Scholar
  3. 3.
    Haley EC Jr, Kassell NF, Torner JC. The International Cooperative Study on the Timing of Aneurysm Surgery. The North American experience. Stroke. 1992;23:205–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Amenta F, Tomassoni D, Traini E, Mignini F, Veglio F. Nicardipine: a hypotensive dihydropyridine-type calcium antagonist with a peculiar cerebrovascular profile. Clin Exp Hypertens. 2008;30:808–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Reddy P, Yeh YC. Use of injectable nicardipine for neurovascular indications. Pharmacotherapy. 2009;29:398–409.PubMedCrossRefGoogle Scholar
  6. 6.
    Haley EC Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78:537–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Badjatia N, Topcuoglu MA, Pryor JC, et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004;25:819–26.PubMedGoogle Scholar
  8. 8.
    Avitsian R, Fiorella D, Soliman MM, Mascha E. Anesthetic considerations of selective intra-arterial nicardipine injection for intracranial vasospasm: a case series. J Neurosurg Anesthesiol. 2007;19:125–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Linfante I, Delgado-Mederos R, Andreone V, Gounis M, Hendricks L, Wakhloo AK. Angiographic and hemodynamic effect of high concentration of intra-arterial nicardipine in cerebral vasospasm. Neurosurgery. 2008;63:1080–6. discussion 1086–1087.PubMedCrossRefGoogle Scholar
  10. 10.
    Tejada JG, Taylor RA, Ugurel MS, Hayakawa M, Lee SK, Chaloupka JC. Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions. AJNR Am J Neuroradiol. 2007;28:844–8.PubMedGoogle Scholar
  11. 11.
    Nogueira RG, Lev MH, Roccatagliata L, et al. Intra-arterial nicardipine infusion improves CT perfusion-measured cerebral blood flow in patients with subarachnoid hemorrhage-induced vasospasm. AJNR Am J Neuroradiol. 2009;30:160–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 1992;77:842–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Campbell BC, Kelman AW, Hillis WS. Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects. Br J Clin Pharmacol. 1985;20(Suppl 1):55S–61S.PubMedGoogle Scholar
  14. 14.
    Cheung AT, Guvakov DV, Weiss SJ, Savino JS, Salgo IS, Meng QC. Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function. Anest Analg. 1999;89:1116–23.CrossRefGoogle Scholar
  15. 15.
    Stullken EH Jr, Balestrieri FJ, Prough DS, McWhorter JM. The hemodynamic effects of nimodipine in patients anesthetized for cerebral aneurysm clipping. Anesthesiology. 1985;62:346–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Zubkov AY, Lewis AI, Scalzo D, Bernanke DH, Harkey HL. Morphological changes after percutaneous transluminal angioplasty. Surg Neurol. 1999;51:399–403.PubMedCrossRefGoogle Scholar
  17. 17.
    Smith RR, Clower BR, Grotendorst GM, Yabuno N, Cruse JM. Arterial wall changes in early human vasospasm. Neurosurgery. 1985;16:171–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Cross DT 3rd, Moran CJ, Angtuaco EE, Milburn JM, Diringer MN, Dacey RG Jr. Intracranial pressure monitoring during intraarterial papaverine infusion for cerebral vasospasm. AJNR Am J Neuroradiol. 1998;19:1319–23.PubMedGoogle Scholar
  19. 19.
    Carhuapoma JR, Qureshi AI, Tamargo RJ, Mathis JM, Hanley DF. Intra-arterial papaverine-induced seizures: case report and review of the literature. Surg Neurol. 2001;56:159–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Sehy JV, Holloway WE, Lin SP, Cross DT III, Derdeyn CP, Moran CJ. Improvement in angiographic cerebral vasospasm after intra-arterial verapamil administration. AJNR Am J Neuroradiol. 2010;31(10):1923–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Mazumdar A, Rivet DJ, Derdeyn CP, Cross DT III, Moran CJ. Effect of intraarterial verapamil on the diameter of vasospastic intracranial arteries in patients with cerebral vasospasm. Neurosurg Focus. 2006;21:E15.PubMedCrossRefGoogle Scholar
  22. 22.
    Keuskamp J, Murali R, Chao KH. High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008;108:458–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Feng L, Fitzsimmons BF, Young WL, et al. Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. AJNR Am J Neuroradiol. 2002;23:1284–90.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Neil Rosenberg
    • 1
  • Marc A. Lazzaro
    • 1
  • Demetrius K. Lopes
    • 2
  • Shyam Prabhakaran
    • 1
  1. 1.Department of Neurological SciencesRush University Medical CenterChicagoUSA
  2. 2.Department of NeurosurgeryRush University Medical CenterChicagoUSA

Personalised recommendations